v2.2
Contact
News
Diagnosing DIRD
Browse
Available on AppStore
The Drug-Induced Respiratory Disease Website
Philippe Camus, M.D.
Dijon, France
Browse by »
Drugs
Patterns
XVII.ah
Pulmonary pasteurellosis
Last update :
01/01/1970
Causative drugs
1
Tocilizumab
I.b
I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d
I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.y
I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
VIII.h
VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.h - Vocal cord dysfunction, adduction, closure, injury
X.k
X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
XVII.b
XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections
XVII.g
XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.ah
XVII - Infections & related conditions
XVII.ah - Pulmonary pasteurellosis
1
1
Search
Search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist